What is the safest muscle relaxant for a patient with idiopathic intracranial hypertension without papilledema?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Safest Muscle Relaxant in IIHWOP

For patients with idiopathic intracranial hypertension without papilledema (IIHWOP), benzylisoquinoline muscle relaxants—specifically atracurium or cisatracurium—are the safest choice, as they have minimal effects on intracranial pressure (ICP) and do not depend on organ function for elimination.

Rationale and Evidence-Based Approach

The primary concern when selecting a muscle relaxant for patients with IIH (with or without papilledema) is avoiding agents that could increase ICP or compromise cerebral perfusion. While IIHWOP patients have elevated ICP without visible papilledema 1, they still require the same precautions regarding ICP management.

Why Benzylisoquinoline Agents Are Preferred

Atracurium and cisatracurium are the optimal choices because:

  • Minimal ICP effects: All currently available neuromuscular blocking agents (NMBAs) have minimal effects on ICP and systemic blood pressure when administered as a single dose 2
  • Organ-independent elimination: Approximately 50% of atracurium is eliminated through Hofmann degradation and ester hydrolysis, making it independent of renal or hepatic function 3
  • Predictable pharmacokinetics: These agents maintain similar pharmacodynamics in patients with organ dysfunction 3
  • Proven efficacy in neurosurgical patients: In a prospective crossover study of 18 sedated neurosurgical patients with Glasgow Coma Scale <7, both vecuronium and atracurium were equally effective in mitigating cough and changes in ICP during tracheal suctioning 2

Agents to Avoid or Use with Caution

Avoid depolarizing agents (succinylcholine) in patients with:

  • Chronic neurological conditions
  • Prolonged immobility
  • Risk of hyperkalaemia 3

Use steroidal agents (rocuronium, vecuronium, pancuronium) with awareness that:

  • Some patients may be sensitive to vagolytic effects (pancuronium, rocuronium) 2
  • Rocuronium and vecuronium are primarily eliminated renally/hepatically, making dosing less predictable in organ dysfunction 3
  • However, they remain acceptable alternatives if benzylisoquinoline agents are unavailable

Clinical Implementation

When administering muscle relaxants to IIHWOP patients:

  1. First-line choice: Atracurium or cisatracurium at standard dosing
  2. Monitor neuromuscular blockade: Use train-of-four monitoring to avoid overdosing
  3. Pretreatment considerations: Combining opioids with NMBAs reduces procedure-related ICP elevation more effectively than opioids alone 2
  4. Reversal agent: Sugammadex is preferred for reversal of steroidal muscle relaxants if used 3

Important Caveats

  • No muscle relaxant is absolutely contraindicated in IIH patients based on ICP concerns alone 2, 4
  • Individual patient factors (renal/hepatic function, comorbidities) may influence agent selection beyond ICP considerations
  • Recent evidence (2025) confirms that skeletal muscle relaxants do not cross the blood-brain barrier and can actually lower ICP by reducing intrathoracic and central venous pressure 4
  • The distinction between IIH with and without papilledema does not change muscle relaxant selection, as both conditions involve elevated ICP 1

Bottom Line

Choose atracurium or cisatracurium as your default muscle relaxant in IIHWOP patients. These benzylisoquinoline agents offer the most predictable pharmacology with minimal ICP effects and organ-independent elimination, making them the safest option for this population 3, 2.

References

Guideline

idiopathic intracranial hypertension: consensus guidelines on management.

Journal of Neurology, Neurosurgery and Psychiatry, 2018

Research

Skeletal Muscle Relaxants and Their Impact on Intracranial Pressure in Neurosurgery.

Medical science monitor : international medical journal of experimental and clinical research, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.